Wells Fargo raises Abbvie stock price target to $340 on pipeline

Wells Fargo raised its AbbVie price target to $340 from $300, citing pipeline additions and higher estimates for Juvmo and etentamig; it now estimates 2035 sales of approximately $107 billion, up from approximately $95 billion. The firm models 2026 sales of $67.8 billion, in line with company guidance. Separately, AbbVie’s third-quarter 2026 adjusted EPS of $3.82 and revenue of $17.4 billion modestly beat estimates, and the company raised its full-year outlook and quarterly dividend.

Analysis

The key asymmetry is duration: near-term immunology execution supports earnings, but much of the incremental valuation case rests on pipeline assets and a 2035 sales forecast. That makes the target increase more sensitive to clinical, regulatory, and launch assumptions than to the latest quarter. After a sharp rerating and with the stock near its recent high, another upward estimate revision may be needed to sustain momentum; a target-price change alone is not a catalyst.

For the next 1–3 months, focus on whether guidance and prescription trends confirm the expected ramp, rather than extrapolating analyst models. Over 6–18 months, successful label expansion and pipeline readouts could support longer-duration value, while setbacks would expose the multiple to compression. The financing-related interest expense revisions are a reminder that pipeline investment has a carrying cost; verify the scale and timing against debt repayment and cash generation.

Contrarian angle: the bullish narrative may underweight concentration in a small number of growth products and the gap between pipeline valuation and realized sales. Conversely, treating the recent rally as proof of overvaluation could miss further earnings revisions. No evidence here establishes that competitive pressure or the pipeline outlook has materially changed; monitor peer launches and prescribing data rather than assume share loss.

Key Decisions for Investors

• Do not chase ABBV solely on the higher target. Hold existing exposure only if the thesis is tied to earnings delivery; consider trimming into strength if the position is sized for a lower-volatility pharma profile.
• Use the next guidance update and prescription data as the 1–3 month decision point: sustained growth and reaffirmed outlook support the bull case; a ramp miss or guidance reduction falsifies it.
• Treat ABBV-466, ABBV-969, and bretisilocin as contingent, long-dated value—not current earnings support. Reassess after clinical or regulatory milestones and compare realized contribution with the assumptions behind the higher long-term sales forecast.
• Watch interest expense, debt repayment, and cash generation together. If financing costs rise without corresponding commercial progress, reduce confidence in pipeline-led valuation expansion.